Payment overview · 2025
General Payments
$389.97
21 reported records · 10 companies
Healthcare provider profile · identity verified
Javed Hafeez, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SUN CITY CENTER, FL · NPI 1588612337
Verified facts
What the public records show
CMS Open Payments records show Javed Hafeez, M.D. received $389.97 in general payments during 2025 across 21 reported records.
Amgen Inc. accounted for 20.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $79.97 | 20.5% | 5 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $57.20 | 14.7% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $53.67 | 13.8% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $44.47 | 11.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $38.13 | 9.8% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $33.57 | 8.6% | 2 | 2025 |
| MicroTransponder, Inc. | Unresolved — no canonical attribution shown | $22.87 | 5.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $21.37 | 5.5% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $20.87 | 5.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.85 | 4.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $389.97 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $57.20 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $44.77 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $44.77 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $44.47 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $35.20 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $33.57 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $31.80 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $21.87 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $21.37 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $21.10 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $20.87 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.24 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 83 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
83 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 520 | 143 |
| Amlodipine Besylate | Amlodipine Besylate | 492 | 131 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 452 | 125 |
| Atorvastatin Calcium | Atorvastatin Calcium | 406 | 97 |
| Levothyroxine Sodium | Levothyroxine Sodium | 342 | 89 |
| Eliquis | Apixaban | 290 | 38 |
| Gabapentin | Gabapentin | 270 | 55 |
| Escitalopram Oxalate | Escitalopram Oxalate | 256 | 59 |
| Simvastatin | Simvastatin | 242 | 57 |
| Alprazolam | Alprazolam | 239 | 57 |
| Metformin Hcl | Metformin Hcl | 223 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 189 | 52 |
| Lisinopril | Lisinopril | 184 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 181 | 47 |
| Furosemide | Furosemide | 168 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 149 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 146 | 41 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 137 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 136 | 39 |
| Omeprazole | Omeprazole | 132 | 39 |
| Glimepiride | Glimepiride | 130 | 30 |
| Carvedilol | Carvedilol | 126 | 35 |
| Allopurinol | Allopurinol | 110 | 22 |
| Finasteride | Finasteride | 105 | 25 |
| Clonazepam | Clonazepam | 101 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 101 | 34 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 90 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 89 | 20 |
| Trazodone Hcl | Trazodone Hcl | 88 | 14 |
| Atenolol | Atenolol | 84 | 23 |
| Memantine Hcl | Memantine Hcl | 84 | 22 |
| Tramadol Hcl | Tramadol Hcl | 84 | 24 |
| Amoxicillin | Amoxicillin | 83 | 62 |
| Jardiance | Empagliflozin | 83 | 15 |
| Potassium Chloride | Potassium Chloride | 82 | 24 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 69 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | 14 |
| Mirtazapine | Mirtazapine | 69 | 21 |
| Meloxicam | Meloxicam | 67 | 20 |
| Temazepam | Temazepam | 66 | 21 |
| Lorazepam | Lorazepam | 65 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 62 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 62 | 17 |
| Montelukast Sodium | Montelukast Sodium | 61 | 23 |
| Ezetimibe | Ezetimibe | 59 | 17 |
| Valsartan | Valsartan | 57 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 55 | 17 |
| Azithromycin | Azithromycin | 54 | 38 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 54 | 15 |
| Januvia | Sitagliptin Phosphate | 49 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | 11 |
| Pregabalin | Pregabalin | 45 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | suppressed |
| Spironolactone | Spironolactone | 43 | 12 |
| Prednisone | Prednisone | 41 | 28 |
| Buspirone Hcl | Buspirone Hcl | 38 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Cefdinir | Cefdinir | 35 | 25 |
| Famotidine | Famotidine | 35 | 13 |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 34 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 31 | suppressed |
| Cephalexin | Cephalexin | 30 | 20 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 30 | 17 |
| Estradiol | Estradiol | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 28 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Methocarbamol | Methocarbamol | 28 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 27 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 27 | 12 |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Latanoprost | Latanoprost | 27 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 18 |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Phenobarbital | Phenobarbital | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Clonidine | Clonidine | 23 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 11 |
| Diazepam | Diazepam | 22 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Felodipine Er | Felodipine | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 19 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 13 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Jantoven | Warfarin Sodium | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Klor-Con 8 | Potassium Chloride | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Ramelteon | Ramelteon | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Ozempic | Semaglutide | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 11 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $389.97 · 21 records | Amgen Inc. | AUSTEDO XR, BREZTRI, EVENITY, GEMTESA, JARDIANCE, KISUNLA, OTEZLA, PROLIA, QUTENZA, REPATHA, REXULTI, VRAYLAR, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error